You cannot register for this webinar

Join us for an important webinar on a next-generation oral FGFR inhibitor, Tinengotinib, being studied for cholangiocarcinoma (CCA) patients whose cancer progressed after chemotherapy and FGFR inhibitor treatment. Experts will discuss how Tinengotinib works, results from early studies, and details about the ongoing Phase III clinical trial. Presenters: Dr. Milind Javle – Professor, MD Anderson Cancer Center Dr. Jean Fan – Chief Medical Officer, TransThera Sciences Don’t miss this opportunity to learn more about a promising treatment under investigation.